{"DataElement":{"publicId":"12943986","version":"1","preferredName":"Combination Prostate Biopsy NCCN Prostate Cancer Risk Stratification Magnetic Resonance Imaging Category","preferredDefinition":"The NCCN prostate cancer risk stratification group using combination prostate biopsy as determined by magnetic resonance imaging.","longName":"COMBX_NCCN_MRI_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"12940055","version":"1","preferredName":"Combination Prostate Biopsy National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease Magnetic Resonance Imaging","preferredDefinition":"A method for prostate needle biopsy that uses both targeted prostate biopsy and systematic prostate biopsy. Combined biopsy provides more accurate diagnosis than MRI-targeted biopsies alone._A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.:Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","longName":"12940053v1.00:7203638v1.00","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"12940053","version":"1","preferredName":"Combination Prostate Biopsy National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease","preferredDefinition":"A method for prostate needle biopsy that uses both targeted prostate biopsy and systematic prostate biopsy. Combined biopsy provides more accurate diagnosis than MRI-targeted biopsies alone._A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.","longName":"C192891:C181084","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Combination Prostate Biopsy","conceptCode":"C192891","definition":"A method for prostate needle biopsy that uses both targeted prostate biopsy and systematic prostate biopsy. Combined biopsy provides more accurate diagnosis than MRI-targeted biopsies alone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease","conceptCode":"C181084","definition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CFB27C-B84C-5FAE-E053-731AD00A7B3D","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7203638","version":"1","preferredName":"Magnetic Resonance Imaging","preferredDefinition":"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","longName":"C16809","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnetic Resonance Imaging","conceptCode":"C16809","definition":"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0ACD8A1-9FD1-5FAA-E053-F662850A96BA","latestVersionIndicator":"Yes","beginDate":"2020-03-12","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-12","modifiedBy":"ONEDATA","dateModified":"2020-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CFB47B-9CCC-5FDF-E053-731AD00AD0BE","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12939854","version":"1","preferredName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease Category","preferredDefinition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy._A grouping of items based on some commonality or by user defined characteristics.","longName":"PC_RSK_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"45","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Very Low Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940069","version":"1","preferredName":"NCCN Prostate Cancer Very Low Risk Group","longName":"12940069v1.00","preferredDefinition":"A prostate cancer risk group characterized by: clinical stage T1c, biopsy Gleason score of 6 or less, and PSA level less than 10.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Very Low Risk Group","conceptCode":"C192873","definition":"A prostate cancer risk group characterized by: clinical stage T1c, biopsy Gleason score of 6 or less, and PSA level less than 10.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116C-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117C-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Low Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940070","version":"1","preferredName":"NCCN Prostate Cancer Low Risk Group","longName":"12940070v1.00","preferredDefinition":"A prostate cancer risk group characterized by: clinical stage T1-T2a, biopsy Gleason score of 6 or less, and PSA level less than 10 ng/mL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Low Risk Group","conceptCode":"C192874","definition":"A prostate cancer risk group characterized by: clinical stage T1-T2a, biopsy Gleason score of 6 or less, and PSA level less than 10 ng/mL.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116D-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117D-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Favorable-Intermediate Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940071","version":"1","preferredName":"NCCN Prostate Cancer Favorable-Intermediate Risk Group","longName":"12940071v1.00","preferredDefinition":"A prostate cancer risk group characterized by: Gleason score of 3 + 4 or less, positive biopsy cores less than 50%, and at most 1 determinant of intermediate risk.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Favorable-Intermediate Risk Group","conceptCode":"C192876","definition":"A prostate cancer risk group characterized by: Gleason score of 3 + 4 or less, positive biopsy cores less than 50%, and at most 1 determinant of intermediate risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116E-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117E-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Unfavorable-Intermediate Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940072","version":"1","preferredName":"NCCN Prostate Cancer Unfavorable-Intermediate Risk Group","longName":"12940072v1.00","preferredDefinition":"A prostate cancer risk group characterized by: primary Gleason pattern 4, positive biopsy cores greater than or equal to 50%, or multiple determinants of intermediate risk.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Unfavorable-Intermediate Risk Group","conceptCode":"C192877","definition":"A prostate cancer risk group characterized by: primary Gleason pattern 4, positive biopsy cores greater than or equal to 50%, or multiple determinants of intermediate risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116F-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117F-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"High Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940073","version":"1","preferredName":"NCCN Prostate Cancer High Risk Group","longName":"12940073v1.00","preferredDefinition":"A prostate cancer risk group characterized by: clinical stage T3a, or biopsy Gleason score 8-10, or PSA level greater than 20 ng/mL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer High Risk Group","conceptCode":"C192878","definition":"A prostate cancer risk group characterized by: clinical stage T3a, or biopsy Gleason score 8-10, or PSA level greater than 20 ng/mL.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-1170-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-1180-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Very High Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940074","version":"1","preferredName":"NCCN Prostate Cancer Very High Risk Group","longName":"12940074v1.00","preferredDefinition":"A prostate cancer risk group characterized by clinical stage T3b or T4, biopsy Gleason score 9 or 10, or N1, N2, or N3 with any stage T, or M1 with any stage T.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Very High Risk Group","conceptCode":"C192879","definition":"A prostate cancer risk group characterized by clinical stage T3b or T4, biopsy Gleason score 9 or 10, or N1, N2, or N3 with any stage T, or M1 with any stage T.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-1171-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-1181-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12939853","version":"1","preferredName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease Category","preferredDefinition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy._A grouping of items based on some commonality or by user defined characteristics.","longName":"12939853v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease","conceptCode":"C181084","definition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F7DC-ACE6-6510-E053-731AD00A15B5","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F7DC-ACED-6510-E053-731AD00A15B5","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"MRI (Risk Stratification Using Combination Biopsy (Systematic + Targeted)","type":"Preferred Question Text","description":"MRI (Risk Stratification Using Combination Biopsy (Systematic + Targeted)","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D11BE0-74AE-0B07-E053-731AD00AF816","latestVersionIndicator":"Yes","beginDate":"2023-03-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"}}